Belvedere Trading
PRQR icon

Belvedere Trading’s ProQR Therapeutics PRQR Stock Holding History

Belvedere Trading’s Portfolio PRQR Stock Details PRQR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q1 		– Sell
-46,100
Closed -$234K – 596
2021
Q4 		$234K Buy
+46,100
New +$351K 0.01% 184

Other funds holding PRQR

PFM
Privium Fund Management Amsterdam, Netherlands $480M AUM 77.45% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
MCM
M28 Capital Management Stamford, Connecticut $53.8M AUM 28.63% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
DCM
DAFNA Capital Management Los Angeles, California $440M AUM 109.12% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return

Belvedere Trading's PRQR Position: Q1 2023 in Review

Belvedere Trading sold out of ProQR Therapeutics (PRQR) in Q1 2023, closing a stake of 11,357 shares — an estimated $42K sold.

Belvedere Trading first reported a position in PRQR in Q4 2022 and held it in 1 quarter. The position peaked at $42K in Q4 2022. 55 funds tracked by Wall St. Rank hold PRQR as of Q1 2023.

  • Belvedere Trading reported no remaining ProQR Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Belvedere Trading sold 11,357 ProQR Therapeutics shares in Q1 2023, an estimated $42K.
  • Belvedere Trading first reported a position in ProQR Therapeutics in Q4 2022 and held it in 1 quarter.
  • Belvedere Trading's ProQR Therapeutics position peaked at $42K in Q4 2022.
  • 55 funds tracked by Wall St. Rank held ProQR Therapeutics as of Q1 2023.

Based on Belvedere Trading's 13F filing for Q1 2023, filed 15 May 2023.